GSK has announced an agreement with Protas to streamline clinical trials of vaccines and therapeutics. 

The three-year agreement sets out to build on an existing two-year relationship and will broaden the scope of work across numerous projects. This includes Phase II and III trials within GSK’s respiratory, immunology, inflammation, vaccines and infectious disease therapeutic areas.  

Protas says it will provide GSK with a variety of scientifically led and operational expertise to improve trial quality, speed, efficiency and participation. 

“Our top priority is to accelerate development of life-changing medicines so they reach patients fast,” said Phillippa Brown, SVP, Head of Development Operations, GSK. 

“Extending our collaboration with Protas will help us reimagine clinical trials to be even more precise and effective, making the most of technologies now available. This is one way we are accelerating our late-stage pipeline to help patients who are waiting.” 

“Our work with GSK embodies what Protas was set up to achieve for our customers and patients alike,” added Sir Martin Landray, Chief Executive Officer of Protas. 

“With Protas’ fusion of smart trial design and innovative technology, we are able to unlock significant benefits in the quality, speed and efficiency of clinical trials and to improve access for participants. 

“We are delighted to be growing our relationship with GSK and applying our approach yet more broadly, helping new treatments reach patients faster.”